These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2007-002742-38 Neutropénie modérée persistante : intérêt d'une administration du G-CSF (granocytes colony stimulating factor) 1 jour sur 2 pour maintenir la dose intensité. Essai de phase III multicentrique chez des... not-yet-due
Ongoing 2007-005706-44 Etude de phase II évaluant l'association topotécan-lapatinib chez des patientes en rechute moins de 12 mois après une première ligne de chimiothérapie à base de platine pour un cancer de l'ovaire, de ... not-yet-due
Reported results 2009-016968-37 Evaluation de l’intérêt d’un dosage des anticorps anti-cetuximab dans la prise en charge thérapeutique des patients présentant un cancer colique ou des voies aéro-digestives supérieures et candidats à... 2013-05-29 due-trials
Completed, but no date Terminated 2012-000045-12 Relation entre la tolérance de l’évérolimus et la concentration sanguine résiduelle d’évérolimus pour le traitement du carcinome rénal avancé bad-data
Reported results 2015-000193-35 A phase II study of ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer Etude de phase II évaluant l’intérêt de l'ABT-263 en monothérapie dans le cancer de ... 2019-03-08 due-trials
Reported results 2015-005017-71 Diagnostic value of 18F-choline PET in patients with indeterminate cytology thyroid nodule : A pilot study Intérêt diagnostique de la TEP à la 18-F Choline chez les patients porteurs d’un nodule th... 2019-05-15 due-trials
Ongoing 2016-001248-20 Impact of new generation hormono-therapy on cognitive functions in elderly patients treated for a metastatic prostate cancer Impact des hormonothérapies de nouvelles générations sur les fonctions c... not-yet-due
Exempt 2016-003468-38 Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients not-yet-due
Completed, but no date 2019-000274-36 Phase III trial comparing 2 diagnostic strategies for the preoperative localization of parathyroid adenoma in primary hyperparathyroidism: TEMP / CT with Tc99m-sestaMIBI or PET / CT with F18-choline i... bad-data
Completed, but no date 2019-000727-41 A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR m... bad-data
Completed, but no date 2019-002184-97 A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure Etude de phase II évaluant l’efficacité et la tolérance... bad-data
Ongoing 2019-002968-27 Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration (3.7 GBq I131 after rhTSH) versus decision of r... not-yet-due
Ongoing 2020-001105-24 TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phase 2 trial TALazoparib et Avelumab en tant que traitement... not-yet-due
Ongoing 2020-003671-17 Nanoparticle reirradiation and hypofractionated protontherapy of pan-tumor relapse: non-randomized phase II study. Réirradiation par nanoparticules et protonthérapie hypofractionnée des rechutes pa... not-yet-due
Ongoing 2020-004497-21 Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A phase II study (GASPAR) not-yet-due